Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Statins may lower glaucoma risk and reduce treatment needs (opens in a new tab)

news-medical.net · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of six check out. Three claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedTaking statins is linked to a lower risk of developing glaucoma and a reduced chance of it getting worse, according to research published online in the British Journal of Ophthalmology.View evidenceHide evidence

Why this verdict

The paper profile supports an association between statin use and lower incident open-angle glaucoma risk, and a separate association with lower treatment-escalation outcomes. However, the headline wording that glaucoma is less likely to be 'getting worse' converts treatment escalation into disease worsening/progression, which is not directly established in the abstract-level paper profile. The headline therefore outruns the more careful treatment-escalation framing in the story body.

1

Study evidence

Statin use was associated with lower hazard of incident open-angle glaucoma in a large matched TriNetX cohort.5-year HR 0.85 (95% CI 0.82 to 0.89); 10-year HR 0.90 (95% CI 0.87 to 0.93).

“Retrospective cohort study using the TriNetX database”
2

Study evidence

Statin use was associated with lower rates of initiation of topical ocular hypotensive medication among patients with glaucoma.5 years: HR 0.89 (95% CI 0.86 to 0.91); 10 years: HR 0.88 (95% CI 0.86 to 0.91)

“The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use.”
Claim 2 of 6Not coveredResearchers searched a large global database covering 165 million individuals and compared more than 210,000 statin users with 210,000 matched nonusers who had ophthalmological follow-up.View evidenceHide evidence

As stated165 million individuals; more than 210,000 statin users and 210,000 matched controls

Why this verdict

The abstract-level profile supports a TriNetX retrospective matched-cohort design and reports 210,701 matched patients in the OAG incidence analysis. It does not verify the story's specific description of a 'large global database covering 165 million individuals' or clearly verify the stated comparison as more than 210,000 statin users versus 210,000 matched nonusers.

1

Study evidence

Statin use was associated with lower hazard of incident open-angle glaucoma in a large matched TriNetX cohort.5-year HR 0.85 (95% CI 0.82 to 0.89); 10-year HR 0.90 (95% CI 0.87 to 0.93).

“Retrospective cohort study using the TriNetX database”
Claim 3 of 6Not coveredStatin use was associated with a 15% lower risk of developing open-angle glaucoma, and at five years there were 4,771 new diagnoses in the statin group versus 5,491 in the control group.View evidenceHide evidence

As stated15% lower risk; 4,771 vs 5,491 diagnoses at five years

Why this verdict

The abstract-level profile supports the 5-year association with lower incident OAG risk, reported as HR 0.85, which corresponds to about a 15% lower hazard. However, the specific event counts of 4,771 versus 5,491 diagnoses are not present in the supplied abstract-level profile, so that part cannot be verified at this depth.

1

Study evidence

Statin use was associated with lower hazard of incident open-angle glaucoma in a large matched TriNetX cohort.5-year HR 0.85 (95% CI 0.82 to 0.89); 10-year HR 0.90 (95% CI 0.87 to 0.93).

“Retrospective cohort study using the TriNetX database”
Claim 4 of 6Not coveredThe article notes that the study is observational, that the authors lacked individual patient data such as intraocular pressure measurements or surgical details, and that prospective randomized trials are needed.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study was retrospective/observational and that prospective trials are needed. But the specific limitations about lacking individual patient data such as intraocular pressure measurements or surgical details, and the need for prospective randomized trials specifically, are not established in the supplied abstract-level profile.

1

Study evidence

Statin use was associated with lower hazard of incident open-angle glaucoma in a large matched TriNetX cohort.5-year HR 0.85 (95% CI 0.82 to 0.89); 10-year HR 0.90 (95% CI 0.87 to 0.93).

“Retrospective cohort study using the TriNetX database”
2

Study evidence

Statin use was associated with lower rates of initiation of topical ocular hypotensive medication among patients with glaucoma.5 years: HR 0.89 (95% CI 0.86 to 0.91); 10 years: HR 0.88 (95% CI 0.86 to 0.91)

“The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use.”
Claim 5 of 6SupportedPeople with glaucoma who are taking statins appear less likely to need stronger treatments such as extra eye drops or surgery to keep it under control.View evidenceHide evidence

Why this verdict

The abstract-level profile reports that, among people with glaucoma, statin use was associated with lower hazards of topical ocular hypotensive prescription and procedural/surgical escalation, including incisional surgery, MIGS, and SLT. The claim is hedged and framed associationally as being less likely to need stronger treatments.

1

Study evidence

Statin use was associated with lower rates of initiation of topical ocular hypotensive medication among patients with glaucoma.5 years: HR 0.89 (95% CI 0.86 to 0.91); 10 years: HR 0.88 (95% CI 0.86 to 0.91)

“The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use.”
Claim 6 of 6SupportedIn a separate analysis of people with glaucoma, statin use was linked to lower risk of progression to incisional glaucoma surgery, minimally invasive glaucoma surgery, selective laser trabeculoplasty, and eye-drop use.View evidenceHide evidence

As stated36% lower risk of incisional glaucoma surgery; 55% lower risk of MIGS; 60% lower risk of SLT; 12% lower risk of eye-drop use at five years

Why this verdict

The abstract-level profile supports a separate glaucoma treatment-analysis cohort and reports 5-year lower hazards for incisional glaucoma surgery, MIGS, SLT, and topical ocular hypotensive prescription, matching the stated relative reductions. This is supported insofar as 'progression' is understood as treatment escalation rather than directly measured disease worsening.

1

Study evidence

Statin use was associated with lower rates of initiation of topical ocular hypotensive medication among patients with glaucoma.5 years: HR 0.89 (95% CI 0.86 to 0.91); 10 years: HR 0.88 (95% CI 0.86 to 0.91)

“The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract reports 10-year associations for both incident OAG and treatment-escalation outcomes, in addition to 5-year results.

    The presented story claims focus on 5-year figures and do not mention the 10-year hazard-ratio results reported in the abstract-level profile.

    From Retrospective cohort (TriNetX EHR database); Retrospective matched cohort (TriNetX database)

  • The incidence cohort was restricted to adults over 40 with ophthalmological follow-up within one year prior, which affects generalizability.

    The story mentions ophthalmological follow-up but does not reflect the age restriction or its implications for the population to which the findings apply.

    From Retrospective cohort (TriNetX EHR database)

3 things the story did carry across
  • Statin use was associated with lower incident open-angle glaucoma risk in an adults-over-40 TriNetX retrospective matched cohort with ophthalmological follow-up; the abstract reports HR 0.85 at 5 years and HR 0.90 at 10 years.
  • Among patients with glaucoma, concurrent statin use was associated with lower treatment escalation, including topical ocular hypotensive prescription, incisional glaucoma surgery, MIGS, and SLT.
  • The evidence is observational: a retrospective cohort study using the TriNetX EHR database, so causal conclusions are not warranted and prospective trials are needed.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssociation between statin use and incident open-angle glaucoma (OAG) among adults >40 years using TriNetX retrospective cohort data.Retrospective cohort (TriNetX EHR database)Expand

In plain English

Retrospective cohort analysis of TriNetX EHR data examining the association between statin use and incident open-angle glaucoma (OAG) among adults >40 with recent ophthalmologic follow-up; in a matched cohort of 210,701 patients, statin use was associated with lower hazard of incident OAG at 5 and 10 years.

Key findings

  • Statin use was associated with lower hazard of incident open-angle glaucoma in a large matched TriNetX cohort.5-year HR 0.85 (95% CI 0.82 to 0.89); 10-year HR 0.90 (95% CI 0.87 to 0.93).
“Retrospective cohort study using the TriNetX database”
What this piece can’t prove
  • Authors call for prospective trials to further elucidate the observed association (explicit in abstract).

3 further details could not be confirmed from the summary.

2secondary dataAssociation between concurrent statin use and lower risk of glaucoma treatment escalation (medication initiation and procedural/surgical escalation) among patients with glaucoma using TriNetX retrospective cohort data.Retrospective matched cohort (TriNetX database)Expand

In plain English

Retrospective matched-cohort analysis using the TriNetX electronic health record network evaluated whether concurrent statin use among patients with glaucoma was associated with lower rates of treatment escalation. A matched cohort of 29,598 individuals with glaucoma was analyzed for time-to-event outcomes including initiation of topical ocular hypotensive medications and procedural/surgical escalations (selective laser trabeculoplasty [SLT], minimally invasive glaucoma surgery [MIGS], and incisional glaucoma surgery). At both 5- and 10-year timepoints, statin use was reported to be associated with lower hazards for medication initiation and all listed procedural/surgical escalation endpoints (hazard ratios and 95% CIs reported in abstract). The abstract concludes that statin use is associated with lower risk of glaucoma treatment escalation and calls for prospective trials to further investigate this relationship.

Key findings

  • Statin use was associated with lower rates of initiation of topical ocular hypotensive medication among patients with glaucoma.5 years: HR 0.89 (95% CI 0.86 to 0.91); 10 years: HR 0.88 (95% CI 0.86 to 0.91)
  • Statin use was associated with lower hazard of incisional glaucoma surgery among patients with glaucoma.5 years: HR 0.64 (95% CI 0.58 to 0.71); 10 years: HR 0.68 (95% CI 0.63 to 0.75)
“The OAG treatment analysis consisted of individuals with glaucoma and concurrent statin use.”
What this piece can’t prove
  • Abstract does not specify details of the matching algorithm, covariates used, or other adjustment methods.
  • Outcomes and exposures ascertained from coded EHR data in a secondary database (limitations of coding and misclassification not detailed in abstract).
  • Authors note that prospective trials are needed to further elucidate the relationship between statin use and glaucoma.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Statin use is associated with lower risk of open-angle glaucoma incidence and treatment escalation

British Journal of Ophthalmology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Statin use is associated with lower risk of open-angle glaucoma incidence and treatment escalation

British Journal of Ophthalmology · 2026 · Crossref

Source (opens in a new tab)
Candidate

A Prospective Study to Evaluate the Incidence of Open Angle Glaucoma Vs Primary Angle Closure Glaucoma in a Tertiary Care Centre

Annals of International Medical and Dental Research · 2018 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.